These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
237 related articles for article (PubMed ID: 16628961)
61. COX-2 inhibitors, other NSAIDs, and cardiovascular risk: the seduction of common sense. Graham DJ JAMA; 2006 Oct; 296(13):1653-6. PubMed ID: 16968830 [No Abstract] [Full Text] [Related]
62. The murky world of the COX-2-selective agents. Bjarnason I; Thjodleifsson B Inflammopharmacology; 2005; 13(4):381-93. PubMed ID: 16354391 [No Abstract] [Full Text] [Related]
63. Cardiovascular effects of coxibs. Caporali R; Montecucco C Lupus; 2005; 14(9):785-8. PubMed ID: 16218488 [TBL] [Abstract][Full Text] [Related]
64. Clinical Pharmacology and Cardiovascular Safety of Naproxen. Angiolillo DJ; Weisman SM Am J Cardiovasc Drugs; 2017 Apr; 17(2):97-107. PubMed ID: 27826802 [TBL] [Abstract][Full Text] [Related]
65. [Non-selective NSAIDs and coxibs: what are myths, what are facts?]. MMW Fortschr Med; 2013 Jun; 155(12):56-7. PubMed ID: 23923320 [No Abstract] [Full Text] [Related]
66. [Insights and views about cardiovascular safety of COX2 inhibitors]. Wallentin L Lakartidningen; 2005 Feb 28-Mar 6; 102(9):666, 668, 671. PubMed ID: 15804041 [No Abstract] [Full Text] [Related]
69. Analysis and recommendations for agency action regarding nonsteroidal antiinflammatory drugs and cardiovascular risk. U.S. Food and Drug Administration J Pain Palliat Care Pharmacother; 2005; 19(4):83-97. PubMed ID: 16431839 [TBL] [Abstract][Full Text] [Related]
70. COX-2 selectivity alone does not define the cardiovascular risks associated with non-steroidal anti-inflammatory drugs. Warner TD; Mitchell JA Lancet; 2008 Jan; 371(9608):270-3. PubMed ID: 18207021 [No Abstract] [Full Text] [Related]
71. COX-2 in play at the AHA and the FDA. FitzGerald GA Trends Pharmacol Sci; 2007 Jul; 28(7):303-7. PubMed ID: 17573128 [TBL] [Abstract][Full Text] [Related]
72. [Clinical guidelines "Rational use of nonsteroidal anti-inflammatory drugs (NSAIDs) in clinical practice". Part I]. Redaktsiia Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(4):70-82. PubMed ID: 26288292 [No Abstract] [Full Text] [Related]
73. Coxibs, Traditional NSAIDs, and Cardiovascular Safety Post-PRECISION: What We Thought We Knew Then and What We Think We Know Now. Patrono C; Baigent C Clin Pharmacol Ther; 2017 Aug; 102(2):238-245. PubMed ID: 28378879 [TBL] [Abstract][Full Text] [Related]
74. The problem with NSAIDs: what data to believe? McKellar G; Madhok R; Singh G Curr Pain Headache Rep; 2007 Dec; 11(6):423-7. PubMed ID: 18173976 [TBL] [Abstract][Full Text] [Related]
76. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Antman EM; Bennett JS; Daugherty A; Furberg C; Roberts H; Taubert KA; Circulation; 2007 Mar; 115(12):1634-42. PubMed ID: 17325246 [No Abstract] [Full Text] [Related]
77. Pain killers--bane or boon? (NSAIDs or COXIBs). Joshi SR; Nadkar MY J Assoc Physicians India; 2005 Jul; 53():591-2. PubMed ID: 16190125 [No Abstract] [Full Text] [Related]
78. Is the cardiovascular toxicity of NSAIDS and COX-2 selective inhibitors underestimated in patients with haemophilia? Boban A; Lambert C; Hermans C Crit Rev Oncol Hematol; 2016 Apr; 100():25-31. PubMed ID: 26899022 [TBL] [Abstract][Full Text] [Related]
79. Understanding the COX-2/NSAID dilemma. Roth SH Drugs; 2005; 65(14):1915-7. PubMed ID: 16162017 [No Abstract] [Full Text] [Related]
80. COX-2 controversy: where are we and where do we go from here? Khanna D; Khanna PP; Furst DE Inflammopharmacology; 2005; 13(4):395-402. PubMed ID: 16354392 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]